Phase 3 N=27 Treatment of Insomnia in Elderly Sleep Apnea Patients With Ramelteon (TAK 375)
Insomnia · Obstructive Sleep Apnea
Primary: Sleep Onset Latency — 9.7; 34.4 minutes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,205 Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma
Asthma
Primary: Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils >=300/uL — 0.73; 0.65; 1.33 events/year — p=<0.001
Phase 3 N=111 Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 97.3 percentage of participants
Phase 3 N=233 Lidocaine + Clonidine for Intraoral Anesthesia in Patients With Diabetes Mellitus Type 2
Diabetes Mellitus · Local Anesthesia
Primary: Duration of Intraoral Local Anesthesia — 132.48; 173.27; 182.09; 195.35 minutes — p=<0.05
Phase 3 N=347 Once-Daily Investigational Nasal Spray In Adults And Adolescents With Vasomotor Rhinitis
Vasomotor Rhinitis · Rhinitis, Vasomotor
Primary: Mean Change From Baseline in Daily Reflective Total Nasal Symptom Scores (rTNSS) — -2.11; -2.01 Score on a scale — p=0.604
Phase 3 N=1,038 S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy
Metastatic Cancer · Prostate Cancer
Primary: Compare Survival Between a Control or Standard Therapy Arm of Docetaxel + Placebo + Prednisone With Docetaxel + Atrasentan + Prednisone in Patients With Hormone…
Phase 3 N=35 Effects of Triptorelin Pamoate in Children With Precocious Puberty - Follow up Study
Precocious Puberty
Primary: Percentage of Children With a Stabilisation or Regression of Tanner Pubertal Stage at the End of the Study (Final Visit), Compared to Pretreatment (Month -6) and…
Phase 3 N=15,405 Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older
Herpes Zoster
Primary: Number of Subjects With Confirmed Herpes Zoster (HZ) Cases — 3; 2; 1; 6 Participants — p=<0.0001
Phase 3 N=612 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients
Kidney Transplantation · Renal Transplantation
Primary: Glomular Filtration Rate (GFR) mL/Min Via Nankivell Method at Month 12 - Standard Regimen vs Certican Regimens — 62.62; 60.54; 59.47; 66.36 mL/min per 1.73m² — p=<0.0001
Phase 3 N=218 Topical DHEA Against Vaginal Atrophy
Vaginal Atrophy
Primary: Co-primary Endpoint: Change From Baseline to Week 12 of Vaginal Cell Maturation (Percentage of Parabasal Cells) — 46.7; 65.5; 53.4; 61.8 percentage of parabasal cells
Phase 3 N=369 Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years
Infections, Meningococcal
Primary: Vaccine Response to Meningococcal Antigens (MenA, MenC, MenW-135 and MenY) — 134; 55; 151; 56 Participants
Phase 3 N=126 Does Fish Oil Prevent Depression in Pregnancy and Postpartum?
Depression
Primary: Beck Depression Inventory — 7.9; 6.5; 6.3; 7.4 units on a scale — p=.29
Phase 3 N=241 PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1
Intercritical Gout
Primary: Number of Gout Flares Per Participant Assessed From Day 1 to Day 112 (Week 16) — 1.06; 0.29; 0.21 Number of Gout flares per participant
Phase 3 N=225 Study Utilizing Rilonacept in Gout Exacerbations
Acute Gout Flare
Primary: Change From Baseline in Patient's Assessment of Pain Using a 5-Point Likert Scale (PAP-LS) in Index Joint to Averaged PAP-LS at 24, 48 and 72 Hours — -1.40; -1.55; -0.69…
Phase 3 N=248 PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)
Gout
Primary: Number of Gout Flares Per Participant Assessed From Day 1 to Day 113 (Week 16) — 1.23; 0.35; 0.34 Gout flares